$28.86
1.91% yesterday
Nasdaq, Dec 05, 10:06 pm CET
ISIN
US1421521071
Symbol
CAI

Caris Life Sciences Stock price

$28.86
-0.35 1.20% 1M
+7.86 37.43% 6M
+7.86 37.43% YTD
+7.86 37.43% 1Y
+7.86 37.43% 3Y
+7.86 37.43% 5Y
+7.86 37.43% 10Y
+7.86 37.43% 20Y
Nasdaq, Closing price Fri, Dec 05 2025
+0.54 1.91%
ISIN
US1421521071
Symbol
CAI

Key metrics

Basic
Market capitalization
$8.0b
Enterprise Value
$7.6b
Net debt
positive
Cash
$755.5m
Shares outstanding
282.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.6 | 11.8
EV/Sales
8.2 | 11.2
EV/FCF
negative
P/B
16.7
Financial Health
Equity Ratio
-80.6%
Return on Equity
136.5%
ROCE
-33.4%
ROIC
-152.5%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$931.4m | $678.8m
EBITDA
$-250.9m | $-13.0m
EBIT
$-300.4m | $-94.2m
Net Income
$-998.2m | $-720.5m
Free Cash Flow
$-150.8m
Growth (TTM | estimate)
Revenue
- | 64.7%
EBITDA
- | 94.9%
EBIT
- | 63.4%
Net Income
- | -90.5%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
53.5%
EBITDA
-26.9% | -1.9%
EBIT
-32.3%
Net
-107.2% | -106.1%
Free Cash Flow
-16.2%
More
EPS
$-3.4
FCF per Share
$-0.5
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Caris Life Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Caris Life Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Caris Life Sciences forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Caris Life Sciences forecast:

Buy
92%
Hold
8%

Financial data from Caris Life Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
931 931
-
100%
- Direct Costs 433 433
-
46%
499 499
-
54%
- Selling and Administrative Expenses 615 615
-
66%
- Research and Development Expense 184 184
-
20%
-251 -251
-
-27%
- Depreciation and Amortization 50 50
-
5%
EBIT (Operating Income) EBIT -300 -300
-
-32%
Net Profit -998 -998
-
-107%

In millions USD.

Don't miss a Thing! We will send you all news about Caris Life Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Caris Life Sciences Stock News

Neutral
PRNewsWire
one day ago
IRVING, Texas , Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance ™ (Caris POA), will collectively present 19 studies across a range of breast ca...
Neutral
PRNewsWire
3 days ago
IRVING, Texas , Dec. 2, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute has joined the Caris Precision Oncology Alliance™ (Caris POA).
Neutral
PRNewsWire
14 days ago
IRVING, Texas , Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the selection of 15 physician-scientists to participate in its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum. This competitive two-year program provides early-career oncologists wi...
More Caris Life Sciences News

Company Profile

Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Head office United States
Website www.carislifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today